SBRT for Kidney Cancer
(AQuOS-RCC Trial)

Recruiting in Palo Alto (17 mi)

+1 other location

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Sunnybrook Health Sciences Centre

No Placebo Group

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?Stereotactic body radiotherapy (SBRT) is an emerging radiotherapy technique that precisely delivers high doses of radiation to tumours. It has been investigated as definitive treatment for an increasing variety of primary tumours including lung, liver, prostate, and now renal cell carcinoma (RCC). The principal aims of this study are to prospectively assess quality of life (QoL) and oncologic outcomes in non-surgical patients who receive SBRT for the treatment of RCC.

Eligibility Criteria

This trial is for adults who can't have surgery or choose not to, with kidney tumors larger than 2.5cm or recurring after treatment. They should be diagnosed with renal cell carcinoma (RCC) if possible, or show tumor growth on scans.

Inclusion Criteria

My kidney cancer diagnosis was confirmed by a biopsy or by growth seen on scans.

My cancer lesion is larger than 2.5cm or has come back after treatment.

I cannot undergo surgery for medical reasons or I choose not to have surgery.

+2 more

Participant Groups

The study tests Stereotactic body radiotherapy (SBRT), a high-precision radiation therapy aimed at treating non-surgical patients with RCC to see how it affects their quality of life and cancer control.

1Treatment groups

Experimental Treatment

Group I: SBRTExperimental Treatment1 Intervention

RCC patients

SBRT is already approved in United States, European Union, Canada, Japan for the following indications:

🇺🇸 Approved in United States as SBRT for: